Anaptysbio (ANAB) EBIT (2016 - 2026)
Anaptysbio posted quarterly EBIT of -$34.6 million for Q1 2026, down 25.77% year-on-year from -$46.7 million in Q1 2025, and down 151.77% on a QoQ basis from $66.9 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of EBIT data on file, last reported at -$34.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 25.77% year-over-year to -$34.6 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (up 357.63% YoY), and the FY2025 full-year result was $47.9 million, up 257.05% from the prior year.
- EBIT for Q1 2026 stood at -$34.6 million, down from $66.9 million in the prior quarter.
- Across five years, EBIT topped out at $87.9 million in Q4 2023 and bottomed at -$44.4 million in Q1 2023.
- The 5-year median for EBIT is -$27.8 million (2022), against an average of -$9.8 million.
- The widest annual swing landed in 2022, when EBIT sank 5115.57%; it then soared 438.49% in 2023.
- A 5-year view of EBIT shows it stood at -$26.0 million in 2022, then jumped by 438.49% to $87.9 million in 2023, then decreased by 14.94% to $74.8 million in 2024, then fell by 10.54% to $66.9 million in 2025, then tumbled by 151.77% to -$34.6 million in 2026.
- The last three EBIT figures came in at -$34.6 million (Q1 2026), $66.9 million (Q4 2025), and $34.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -34.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.64 Mn |
| Dec 31, 2025 | 66.90 Mn |
| Sep 30, 2025 | 34.70 Mn |
| Jun 30, 2025 | -26.17 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | 74.78 Mn |
| Sep 30, 2024 | -22.76 Mn |
| Jun 30, 2024 | -40.32 Mn |
| Mar 31, 2024 | -42.20 Mn |
| Dec 31, 2023 | 87.92 Mn |
| Sep 30, 2023 | -37.73 Mn |
| Jun 30, 2023 | -40.14 Mn |
| Mar 31, 2023 | -44.40 Mn |
| Dec 31, 2022 | -25.97 Mn |
| Sep 30, 2022 | -29.63 Mn |
| Jun 30, 2022 | -27.80 Mn |
| Mar 31, 2022 | -31.75 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -6.76 Mn |
| Jun 30, 2021 | -533,000.00 |
| Mar 31, 2021 | -18.36 Mn |
| Dec 31, 2020 | 33.35 Mn |
| Sep 30, 2020 | -24.34 Mn |
| Jun 30, 2020 | -22.64 Mn |
| Mar 31, 2020 | -10.25 Mn |
| Dec 31, 2019 | -22.26 Mn |
| Sep 30, 2019 | -33.75 Mn |
| Jun 30, 2019 | -26.66 Mn |
| Mar 31, 2019 | -24.77 Mn |
| Dec 31, 2018 | -19.66 Mn |
| Sep 30, 2018 | -16.89 Mn |
| Jun 30, 2018 | -14.42 Mn |
| Mar 31, 2018 | -15.76 Mn |
| Dec 31, 2017 | -7.15 Mn |
| Sep 30, 2017 | -9.09 Mn |
| Jun 30, 2017 | -2.56 Mn |
| Mar 31, 2017 | -9.99 Mn |
| Dec 31, 2016 | -3.17 Mn |
| Sep 30, 2016 | -1.08 Mn |
| Jun 30, 2016 | 2.36 Mn |
| Mar 31, 2016 | -1.14 Mn |